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Cyclical changes in production of neuroactive steroids during the oestrous cycle induce signiﬁcant changes in GABAA receptor
expression in female rats. In the periaqueductal grey (PAG) matter, upregulation of α4β1δ GABAA receptors occurs as
progesterone levels fall during late dioestrus (LD) or during withdrawal from an exogenous progesterone dosing regime. The
new receptors are likely to be extrasynaptically located on the GABAergic interneurone population and to mediate tonic currents.
Electrophysiological studies showed that when α4β1δ GABAA receptor expression was increased, the excitability of the output
neurones in the PAG increased, due to a decrease in the level of ongoing inhibitory tone from the GABAergic interneurones.
The functional consequences in terms of nociceptive processing were investigated in conscious rats. Baseline tail ﬂick latencies
were similar in all rats. However, acute exposure to mild vibration stress evoked hyperalgesia in rats in LD and after progesterone
withdrawal, in line with the upregulation of α4β1δ GABAA receptor expression.
Copyright © 2009 T. A. Lovick and A. J. Devall.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The periaqueductal (PAG) grey matter is involved in reg-
ulating a remarkable number of bodily functions. Circuits
controlling nociception, temperature regulation, micturi-
tion, vocalisation, cardiorespiratory function, and sexual
behaviours are all dependent on the functional integrity of
this midbrain region [1–5]. The PAG is also involved in
producing emotional changes, particularly those associated
with fear and defensive behaviour [6, 7], and has the
ability to modulate activity in its various control circuits
to orchestrate changes in the behavioural response pattern
that are appropriate to an ever-changing environment [8].
In females, the PAG operates within a constantly changing
hormonal milieu that results from the cyclical changes
in production of neuroactive gonadal steroids during the
menstrual cycle (oestrous cycle in animals). The lipophilic
nature of these molecules means that they readily gain
access to the brain from the circulation [9]. Here we review
the results of our recent investigations into the functional
consequences of changes in circulating levels of progesterone
during the oestrous cycle in female rats. These experimental
studieshaverevealedremarkablehormone-linked changesin
theintrinsicexcitabilityofthePAGcircuitrythatarereﬂected
by signiﬁcant changes in the behaviour of the animal.
2. Cyclical Changes in Progesterone
Secr etio ninF e m ales
Inwomen,productionofprogesteroneundergoessubstantial
changes during the menstrual cycle. Plasma levels of the
steroid remain at a constant low level during the ﬁrst half
of the cycle. Following ovulation, secretion of progesterone
by the corpus luteum increases, resulting in elevated blood
plasma levels [10]. In the absence of a fertilised ovum the
corpus luteum then degenerates, with an associated rapid fall
in plasma progesterone production prior to menstruation.
It has long been recognised that the cyclical produc-
tion of gonadal hormones during the menstrual cycle can
trigger signiﬁcant changes in psychological status. In up to
75% of women, the late luteal phase of the cycle, when
progesterone levels decline rapidly, is associated with the
development of adverse psychological symptoms; these may
include irritability, mood swings, aggression, and anxiety2 Neural Plasticity
[11]. Additionally, bodily changes such as breast tenderness
andbloatingmayoccurandresponsivenesstopainfulstimuli
becomes enhanced [12, 13]. Importantly, symptoms fail to
develop in women during anovulatory cycles [14] indicating
a causal relationship between changes in gonadal steroid
levels and brain function. The oestrous cycle of rodents
acts as a suitable model of the human menstrual cycle, and
oﬀers the opportunity to study hormone-induced plasticity
of brain function within intact circuits and to relate this to
a behavioural outcome. The late dioestrus (LD) phase in
rats, when progesterone levels are falling naturally, correlates
with the premenstrual phase in women and increased
anxiety and aggression have been reported to develop during
dioestrus in rats [15–17]. In rats progesterone levels also fall
rapidly during proestrus following the preovulatory surge
[18]. However, the dynamics of this short-lasting surge in
progesterone production are not suﬃcient to trigger the
long-lasting changes in GABAergic function that accompany
LD (see below, also [19] for discussion of this point).
3. Neural Actions of the Progesterone
MetaboliteAllopregnanolone
Within the brain, progesterone produces genomic eﬀects
via neuronal nuclear-bound receptors. In addition, it can
also act at the cell membrane level. These nongenomic
eﬀects are mediated not by progesterone itself but via the
actions of its neuroactive metabolite 3 alpha-hydroxy-5
alpha-pregnan-20-one (allopregnanolone, ALLO). ALLO is
a steroidal compound that is synthesized de novo within
the brain from progesterone via the actions of 5α-reductase
and 3α-hydroxysteroid dehydrogenase (for review, see [20]).
ALLO acts at two sites on the GABAA receptor. The ﬁrst
is an activation site that produces direct receptor activation
and the second is a potentiation site at which ALLO acts
as a powerful positive allosteric modulator to enhance
the eﬀects of GABA [21]. Potentiation occurs in response
to low nanomolar concentrations of ALLO [22]w h e r e a s
higher, micromolar concentrations, as seen for example at
parturition [23], are required for direct activation of GABAA
receptors [24]. The levels of ALLO present in the brain are
inﬂuenced by the circulating levels of progesterone and we
have shown recently that ALLO from the plasma gains ready
access to the PAG where it produced a decrease in neuronal
excitability via a GABAA-mediated mechanism [25]. In other
brain structures, changes in the concentration of ALLO
following ﬂuctuations in the level of circulating progesterone




of GABA Receptor Function in the PAG
GABAA receptors are pentameric structures that surround
a single chloride channel. Although most receptors are
comprised of only 3 subunit types, the large pool of available
subunits means that receptors can be comprised of many
diﬀerent subunit combinations [27]. The functional char-
acteristics of individual receptor subtypes are determined
by their subunit composition. There are several indications
that ﬂuctuations in the concentrations of progesterone play a
majorroleindeterminingthetemporalpatternofexpression
of certain subunits of the GABAA receptor. For example,
withdrawal of cultured cerebellar granule cells or cortical
neurones from long-term treatment with progesterone was
accompanied by upregulation of α4 subunit mRNA [28, 29].
Similarly, hippocampal tissue from progesterone-withdrawn
rats showed upregulation of both α4a n dδ subunit mRNA
[26, 30]. These eﬀects were mediated not by progesterone
itselfbutbyitsneuroactivemetaboliteALLOandpresumably
represent a response of the neurone in an eﬀort to maintain
homeostasis. Thus progesterone inﬂuences neural function
directly via a genomic action at the nuclear progesterone
receptor and indirectly via a nongenomic action of ALLO at
the membrane-bound GABAA receptor.
ThePAGisanotherbrainregionthatshowsasusceptibil-
itytophasicchangesintheambientlevelofprogesteroneand
hence ALLO. Using immunohistochemistry, we found that
24-hour withdrawal of female rats from long-term dosing
with exogenous progesterone (5mgKg
−1 IP twice daily for
6 days) leads to upregulation of α4, β1, and δ GABAA
receptor subunit protein in neurones in the PAG (Figure 1)
[31]. Within the PAG, subunit-immunoreactive neurones
were distributed throughout all subdivisions (Figure 2).
However, upregulation after progesterone withdrawal was
most marked in the dorsolateral column [32] where the
density of GABAergic neurones, in which most α4β1δ
receptors are expressed [31], was the greatest [33].
We have been able to translate the ﬁndings obtained
usinganexogenousdosing regimetothenaturalﬂuctuations
in the hormone that occur during the oestrous cycle. During
LD, when plasma levels of progesterone are falling, a parallel
upregulation of α4, β1, and δ GABAA receptor subunit
protein occurred within the PAG [34]. This suggests that
new GABAA receptors with the α4β1δ subunit conﬁguration
had been formed in response to the falling steroid levels
in the brain. GABAA receptors containing δ subunits are
likely to be extrasynaptically located [35] and those with
the α4β1δ conﬁguration are characterised by an extremely
low EC50 for GABA [36]. The α4β1δ GABAA receptors in
the PAG should therefore be activated by the level of GABA
present in the extracellular ﬂuid and be responsible for
mediating tonic currents [35, 36]. Expression of α4, β1,
and δ subunit protein was conﬁned predominantly to the
GABAergic neuronal population in the PAG [32]. These two
factors,thatis,sensitivitytoGABAandcellularlocation,may
provide an important key to the functional consequences
of progesterone withdrawal-induced receptor plasticity. In
functional terms, increased expression of α4β1δ receptors
on GABAergic neurones would be expected to lead to a
reduction in the level of their activity, thus disinhibiting
the output neurones within the PAG by reducing the level
of ongoing GABAergic tone (Figure 3). Hence, one would
expect to see an increase in the excitability of the various
neural control systems located within the PAG. The PAG is
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Figure 1: Density of α4, β1, and δ GABAA receptor subunit-immunoreactive neurones in the PAG in (a) spontaneously cycling female rats
and (b) rats that had undergone a progesterone withdrawal regime. Abbreviations: P: proestrus; O: oestrus; ED: early dioestrus; LD: late
dioestrus; HP: high progesterone; VEH: vehicle treated; PWD: progesterone-withdrawn. n = 5 for each group, all values mean ± SEM.
∗P<. 05, post hoc Fischer test after signiﬁcant (P<. 05) one-way ANOVA. Data redrawn from [31, 32].
α4 β1 δ
Figure 2: Camera lucida reconstruction showing distribution
of α4, β1, and δ GABAA receptor subunit positive neurons in
representative sections taken from the mid PAG level from a rat in
early dioestrus. The ﬁgure is adapted from [31].
columns that integrate and control diverse aspects of its
function [37]. The oestrous cycle-linked upregulation of
α4, β1, and δ GABAA receptor subunit protein was seen in
all regions of the PAG with little evidence of somatotopic
localisation. Hence, the functional consequences of receptor
plasticity are likely to be widespread and not conﬁned to any
one aspect of PAG function.
5. Oestrous Cycle-LinkedChanges inNeural
Excitabilityof the Female PAG
The excitability of the neural circuits of the PAG is normally
regulated by tonic activity of GABAergic neurones. At the
neuronal level, the presence of ongoing GABAergic inhibi-
tionwithinthePAGwasrevealedbytheincreaseinﬁringrate
of output neurones in the presence of a GABAA antagonist
[19]. In the conscious rat, the functional importance of the
tonically active GABAergic control system is manifested by
the dramatic behavioural changes elicited by microinjection
ofGABAA antagonistsintothisregion[39–42].Todate,most
of these studies have been restricted to male animals. How-
ever, given the plasticity of the GABAergic control system in
the PAG in females, changes in the functional excitability of
the neural circuitry might be expected to occur at diﬀerent
stages of the oestrous cycle. Indeed, our electrophysiological
studies have shown that GABA tone in the PAG in females
is reduced during LD [19] and also in oestrus, although the
latter eﬀect is unlikely to be related to plasticity of α4β1δ
receptor expression (for a discussion on this point see [19]).
Changes in the intrinsic level of GABAergic tone in the PAG
have the potential to impact signiﬁcantly on the wide range
of the behaviours that are controlled by this region. Indeed,
even in the anaesthetised preparation, we were able to show
changes in responsiveness of single neurones in the PAG to
the panicogenic and pronociceptive CCK2 receptor agonist
pentagastrin at diﬀerent stages of the cycle [19].
6. BehaviouralConsequences of Steroid
Hormone Withdrawal-Evoked Changes
inPAG Function
The PAG is a source of multiple descending control pathways
to the spinal cord that exert both inhibitory and facili-























Figure 3: Cartoon to depict changes in GABAA receptor expression in the PAG at diﬀerent stages of the oestrous cycle. α4β1δ GABAA
receptors are expressed mainly by GABAergic interneurones where they are extrasynaptically located and mediate tonic currents. The
excitability of output neurons from the PAG is limited by spontaneous activity in GABAergic interneurones. (a) When expression
of α4β1δ GABAA receptors is low during proestrus (Pro), oestrus (O), and early dioestrus (ED), high levels of activity in the interneurone
population limit the excitability of the output neurons. (b) When progesterone levels fall during late dioestrus (LD), increased expression of
α4β1δ receptors leads to an increase in tonic current carried by GABAergic cells, thus limiting their on-going activity. The output neurones
therefore become intrinsically more excitable, and their threshold for activation is lowered. The ﬁgure is adapted from [38].
information [43]. Both pro- and antinociceptive control
systems are thought to be tonically active under normal con-
ditions but the balance between them is in a state of constant
dynamic ﬂux [44, 45]. We have recently begun to investigate
the behavioural consequences of steroid hormone-evoked
changes in the excitability of the circuitry in the conscious
animal, focussing on changes in responsiveness to painful
stimuli as well as on indices of anxiety.
The tail ﬂick latency (TFL) in response to radiant heat
applied to the underside of the tail elicits a withdrawal
reﬂex that is a commonly used index of sensitivity to acute
cutaneous pain in conscious rats [46]. We compared TFLs in
rats that had undergone a progesterone withdrawal regime
(5mgKg
−1 IP twice daily for 6 days followed by 24-hour
withdrawal) with those obtained from rats in proestrus
(Pro) and LD. These two stages of the oestrous cycle were
chosen as being representative of low and high expressions
of α4β1δ GABAA receptors in the PAG (see Figure 1). Since
changing hormone levels might also induce changes in stress
or anxiety levels in rats used for nociception testing, which
could potentially inﬂuence their perception of pain [46], we
also observed the behaviour of animals in a 1m × 1mopen
ﬁeld arena to assess intrinsic anxiety levels [47].
Experiments involving nociceptive testing were carried
out under the UK Animals (Scientiﬁc Procedures) Act 1986
and conformed with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes
of Health (NIH Publication no. 85–23, revised 1985). Female
Wistar rats were habituated to a restraining tube. TFLs
were measured at 5-minute intervals over a 15-minute
period, that is 3 tail ﬂick tests, to obtain a basal value
for TFL. There was no diﬀerence in basal TFLs between
any of the diﬀerent groups of spontaneously cycling rats
or the progesterone-treated animals (Figure 4(a)). Similarly,
there was no diﬀerence in any of the behavioural indices
measured in the open ﬁeld (Table 1). We next investigated
interactions between anxiety and nociception. The rats
were subjected to mild nonnoxious stress by vibrating the
restraining tube with the rat inside it for 5 minutes at
4Hz [48]. During the vibration stress, the rats showed
signs of anxiety that included micturition, defaecation, and
vocalisation. Immediately following the vibration stress,
tail ﬂick testing was resumed. Rats that were undergoing
progesterone-withdrawal had developed a poststress hyper-
algesia that was manifested as a signiﬁcant decrease in tail
ﬂick latency that persisted for 10 minutes (Figure 4(b)). Rats
maintained on the progesterone dosing schedule failed to
develop hyperalgesia (Figure 4(b)). Spontaneously cycling
rats in Pro (low α4β1δ GABAA receptor expression in the
PAG) were compared with rats in LD (high α4β1δ GABAA
receptor expression in the PAG) using the same protocol.
Rats in LD displayed a signiﬁcant hyperalgesia following the
vibrationstress,whereasratsinProshowednochangeinTFL
(Figure 4(b)).
These experiments failed to show any change in baseline
thermal nociception in female Wistar rats at diﬀerent stages
of the oestrous cycle. In contrast, other investigators have
been able to detect oestrous cycle-linked diﬀerences in sen-
sitivity to pain [49–53]. However, the reports of diﬀerences
in nociception with respect to cycle stage were equivocal.Neural Plasticity 5
Table 1: Behavioural indices in open ﬁeld test for rats in proestrus,
late dioestrus,and after progesterone withdrawal. Allvalues mean±
SEM. Late dioestrus (LD, n = 15), proestrus (Pro, n = 22), high






3827 ±228 3737 ±205 4328 ±208
Average speed (cms−1) 12.85 ±0.76 12.91 ±0.70 14.45 ±0.70
Time in central zone
(%)
2.56 ±0.51 1.96 ±0.25 2.82 ±0.56
Time in middle zone
(%)
10.00 ±1.98 7.74 ±1.42 6.75 ±0.94
Time in outer zone (%) 86.60 ±2.24 89.09 ±1.73 90.85 ±1.43
Number of central zone
re-entries
4.25 ±0.64 4.10 ±0.62 3.57 ±0.57
Time rearing (%) 18.53 ±2.35 19.13 ±2.01 14.13 ±1.26
Time freezing (%) 0.30 ±0.30 0.54 ±0.44 n/a
Time grooming (%) 7.68 ±1.51 6.48 ±1.48 4.93 ±1.38
Atbest,itseemsthatcyclestagemayinﬂuenceresponsiveness
to pain in rats but only in some strains and under speciﬁc
experimental conditions. In terms of PAG function, this
suggests either that there is very little oestrous cycle-linked
change in tonic descending control of spinal nociceptive
processing or, alternatively, that the activity in the control
systemsisalteredduringthecyclebutinsuchawaythatthere
is little change in the net balance of control at the spinal cord
level.
In line with the lack of oestrous cycle eﬀect on basal pain
sensitivity, we were also unable to detect any diﬀerences in
basal anxiety levels using the open ﬁeld test. This ﬁnding is
supported by previous studies [54, 55] but not by the work
of Frye et al. [56]whoreported anincrease in anxiety-related
behaviour in a brightly lit open ﬁeld during the dark phase
of the day in rats in dioestrus. However, this study may not
be directly comparable to the present work, since testing in
bright light, as opposed to the relatively subdued lighting
(60lux) used in the present study, would be inherently more
stressful to the rats [57] by compounding the anxiogenic
eﬀects of bright light and exposure to a novel environment.
Interestingly, in the present study oestrous cycle-related
diﬀerences in responsiveness to pain became apparent in
the setting of a mild stress that increased anxiety levels.
Moreover, the oestrous cycle-linked hyperalgesia appeared
only during LD, when α4β1δ receptor expression in the PAG
would be upregulated. Rats undergoing withdrawal from
progesterone,inwhichα4β1δ receptorexpressioninthePAG
would also be upregulated, showed a hyperalgesia, indicating
that the eﬀect seen in the spontaneously cycling animals was
likelytobehormone-linked.Duringtheoestrouscycle,levels
of a number of gonadal hormones change [18]. Oestradiol in
particularhasbeenshowntoaﬀectGABAergicfunction[58].
However, at the time when α4β1δ GABAA receptor expres-
sion increase during LD, plasma oestradiol levels are low and
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Figure 4: (a) Baseline tail ﬂick latency in spontaneously cycling
female Wistar rats in proestrus (Pro) and late dioestrus (LD) and in
rats undergoing progesterone treatment (HP) or withdrawal from
an exogenous progesterone dosingregime(PWD). Datashowmean
values of three readings taken at 5-minute intervals. All values
mean ±SEM. Pro: n = 13, LD: n = 12, HP: n = 8, PWD: n = 7. (b)
Change in tail ﬂick latency (TFL) following 5-minute exposure to
nonnoxious vibration stress in normally cycling and progesterone-
withdrawn female Wistar rats.Data represent mean values obtained
during 10 minutes immediately poststress as a percentage of the
mean baseline level measured during 10 minutes prior to the stress.
A control group comprising rats in proestrus and late dieostrus
received no vibration stress. All values mean ± SEM; no stress
(control): n = 12, Pro: n = 13, LD: n = 12, HP: n = 8, PWD:
n = 7. ∗P<. 05, post hoc Dunnett’s test in comparison to control
group after signiﬁcant (P<. 05) one-way ANOVA.
oestrogen are responsible for the changes in PAG function
during LD. The results of our most recent work indicate that
the PAG may be involved in mediating the oestrous cycle-
linked hyperalgesia in the setting of mild anxiety. We have
found that exposure to the vibration stress regime elicits
diﬀerential expression of the immediate early gene c-fos in
the ventrolateral PAG in rats in Pro and LD (Lovick and
Devall, unpublished work). The ventrolateral PAG contains
neurons that are a source of descending facilitation of spinal
nociceptive inputs [59, 60]. Thus steroid hormone-linked
changes in the excitability of descending control systems
from the PAG may alter the level of descending control
over spinal nociceptive processing and contribute to the
hyperalgesia that develops in LD or during progesterone
withdrawal.6 Neural Plasticity
Recent imaging studies in humans have also implicated
the PAG in anxiety-induced hyperalgesia. Anticipatory anx-
iety in expectation of receiving a painful cutaneous thermal
stimulus led not only to a heightened pain experience when
the stimulus was delivered, that is hyperalgesia, but was
also associated with activation of the PAG [61]. In women,
increased responsiveness to noxious stimulation has been
reported consistently during the luteal phase of menstrual
cycle [12, 13]. In many women, anxiety levels are raised
during the late luteal phase [11]. In any experimental
scenario involving pain testing in human subjects, a degree
of anxiety or apprehension is almost inevitable. Thus it is
possible that the reported menstrual cycle-related diﬀerences
in pain sensitivity in women may to a large extent be
secondary to changes in anxiety levels rather than a primary
response to changing hormone levels.
In female rats, falling progesterone levels can produce
remarkable changes in the functional characteristics of
neurones in the PAG, which may underlie certain oestrous
cycle-linked changes in behaviour. These ﬁndings have
implications for the design and interpretation of behavioural
studies in female rodents in which the stage of the oestrous
cycle may be a signiﬁcant confounding inﬂuence. It is also
possible that such hormone-linked changes may underlie
the development of menstrual cycle-related disorders in
susceptible women.
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